WO1997000319A3 - Chimeric leptin fused to immunoglobulin domain and use - Google Patents

Chimeric leptin fused to immunoglobulin domain and use Download PDF

Info

Publication number
WO1997000319A3
WO1997000319A3 PCT/GB1996/001388 GB9601388W WO9700319A3 WO 1997000319 A3 WO1997000319 A3 WO 1997000319A3 GB 9601388 W GB9601388 W GB 9601388W WO 9700319 A3 WO9700319 A3 WO 9700319A3
Authority
WO
WIPO (PCT)
Prior art keywords
leptin
domain
chimeric
immunoglobulin domain
fused
Prior art date
Application number
PCT/GB1996/001388
Other languages
French (fr)
Other versions
WO1997000319A2 (en
Inventor
Michael Joseph Browne
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Jeffrey Hugh Robinson
Original Assignee
Smithkline Beecham Plc
Michael Joseph Browne
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Jeffrey Hugh Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc, Michael Joseph Browne, Conrad Gerald Chapman, Helen Elizabeth Clinkenbeard, Jeffrey Hugh Robinson filed Critical Smithkline Beecham Plc
Priority to JP9502784A priority Critical patent/JPH11507547A/en
Priority to EP96917584A priority patent/EP0832219A2/en
Priority to AU60110/96A priority patent/AU6011096A/en
Publication of WO1997000319A2 publication Critical patent/WO1997000319A2/en
Publication of WO1997000319A3 publication Critical patent/WO1997000319A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Chimeric leptin which are proteins comprising leptin or a mutant or a variant thereof fused to a human immunogobulin domain. One favoured immunoglobulin domain is the human immunoglobulin Fc domain. The chimeric derivatives of leptin have, despite their large molecular size, good pharmacological activity combined with prolonged clearance rates. These derivatives of leptin are therefore indicated to be particularly useful for the treatment or prophylaxis of obesity or diseases and conditions associated with obesity such as atherosclerosis, hypertension and type II diabetes.
PCT/GB1996/001388 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use WO1997000319A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP9502784A JPH11507547A (en) 1995-06-13 1996-06-11 Chimeric leptin fused with immunoglobulin domain and uses thereof
EP96917584A EP0832219A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use
AU60110/96A AU6011096A (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9511935.0A GB9511935D0 (en) 1995-06-13 1995-06-13 Novel compound
GB9511935.0 1995-06-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US08981783 A-371-Of-International 1998-09-18
US09/859,361 Continuation US20020058311A1 (en) 1995-06-13 2001-05-17 Chimeric leptin fused to immunoglobulin domain and use

Publications (2)

Publication Number Publication Date
WO1997000319A2 WO1997000319A2 (en) 1997-01-03
WO1997000319A3 true WO1997000319A3 (en) 1997-04-10

Family

ID=10775951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/001388 WO1997000319A2 (en) 1995-06-13 1996-06-11 Chimeric leptin fused to immunoglobulin domain and use

Country Status (6)

Country Link
EP (1) EP0832219A2 (en)
JP (1) JPH11507547A (en)
AU (1) AU6011096A (en)
CA (1) CA2224646A1 (en)
GB (1) GB9511935D0 (en)
WO (1) WO1997000319A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310034B1 (en) 1993-05-21 2001-10-30 Ut-Battelle, Llc Agouti polypeptide compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
WO1997018833A1 (en) * 1995-11-22 1997-05-29 Amgen Inc. Methods of increasing lean tissue mass using ob protein compositions
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
ATE267255T1 (en) * 1995-12-27 2004-06-15 Genentech Inc WHETHER PROTEIN DERIVATIVES WITH EXTENDED HALF-LIFE
AU769250B2 (en) * 1995-12-27 2004-01-22 Genentech Inc. OB protein derivatives having prolonged half-life
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
AU770897B2 (en) * 1996-12-20 2004-03-04 Amgen, Inc. OB fusion protein compositions and methods
JP2001512483A (en) * 1997-02-25 2001-08-21 イーライ リリー アンド カンパニー Treatment of infertility with leptin receptor ligand
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
AU2002300605B8 (en) * 1997-04-17 2006-02-09 Amgen Inc. Compositions Comprising Conjugates of Stable, Active, Human OB Protein with Antibody FC Chain and Methods
HU226175B1 (en) * 1997-04-17 2008-06-30 Amgen Inc Human ob protein suspension, process for producing thereof and use for production of pharmaceutical composition
AU8182298A (en) * 1997-07-10 1999-02-08 Beth Israel Deaconess Medical Center Recombinant erythropoietin / immunoglobulin fusion proteins
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
JP2002505086A (en) * 1998-02-25 2002-02-19 レキシジェン ファーマシューティカルズ コーポレイション Enhanced circulating half-life of antibody-based fusion proteins
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
SK9432001A3 (en) * 1999-01-07 2003-02-04 Lexigen Pharm Corp Expression and export of anti-obesity proteins as Fc fusion proteins
EP1177285A1 (en) * 1999-05-07 2002-02-06 Genentech, Inc. Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
AU7699900A (en) * 1999-10-01 2001-05-10 Eli Lilly And Company A novel human leptin homolog
ES2269366T3 (en) * 2000-02-11 2007-04-01 Merck Patent Gmbh IMPROVEMENT OF AVERAGE LIFE IN CIRCULATION OF FUSION PROTEINS BASED ON ANTIBODIES.
AU8178401A (en) 2000-05-22 2001-12-03 Vlaams Interuniv Inst Biotech Receptor-based interaction trap
US7235629B2 (en) 2000-11-14 2007-06-26 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Functional fragment of the leptin receptor
RU2363707C2 (en) * 2001-02-19 2009-08-10 Мерк Патент Гмбх Artificial proteins with lowered adjuvanticity
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
ATE385806T1 (en) * 2003-06-12 2008-03-15 Lilly Co Eli FUSION PROTEINS
BRPI0411132B8 (en) 2003-06-12 2021-05-25 Lilly Co Eli heterologous fusion protein and its uses
CA2545539A1 (en) 2003-10-15 2005-04-28 Pdl Biopharma, Inc. Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
EP1682584B1 (en) 2003-11-13 2013-04-17 Hanmi Science Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7423113B2 (en) 2004-08-25 2008-09-09 Vib Vzw Leptin antagonist
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
US20090232807A1 (en) * 2004-12-22 2009-09-17 Eli Lilly And Company Glp-1 analog fusion protein formulations
AU2007209201A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464533A1 (en) * 1990-06-28 1992-01-08 BEHRINGWERKE Aktiengesellschaft Fusionproteins with parts of immunoglobulins, their production and use
WO1996005309A2 (en) * 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996034885A2 (en) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Biologically active peptide fragments of ob protein
WO1996035787A1 (en) * 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464533A1 (en) * 1990-06-28 1992-01-08 BEHRINGWERKE Aktiengesellschaft Fusionproteins with parts of immunoglobulins, their production and use
WO1996005309A2 (en) * 1994-08-17 1996-02-22 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1996034885A2 (en) * 1995-05-05 1996-11-07 Smithkline Beecham Plc Biologically active peptide fragments of ob protein
WO1996035787A1 (en) * 1995-05-08 1996-11-14 Chiron Corporation Nucleic acids for treating obesity

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YIYING ZHANG ET AL: "POSITIONAL CLONING OF THE MOUSE OBESE GENE AND ITS HUMAN HOMOLOGUE", NATURE, vol. 372, no. 6505, 1 December 1994 (1994-12-01), pages 425 - 432, XP000602062 *

Also Published As

Publication number Publication date
JPH11507547A (en) 1999-07-06
WO1997000319A2 (en) 1997-01-03
CA2224646A1 (en) 1997-01-03
EP0832219A2 (en) 1998-04-01
GB9511935D0 (en) 1995-08-09
AU6011096A (en) 1997-01-15

Similar Documents

Publication Publication Date Title
WO1997000319A3 (en) Chimeric leptin fused to immunoglobulin domain and use
AU5673596A (en) Rapid, stable high-titre production of recombinant retroviru s
AU2551797A (en) Improved tissue destruction in cryosurgery by use of thermal hysteresis proteins
AU4426296A (en) G protein coupled receptor protein, production, and use thereof
AU5801296A (en) Crosslinkable polypeptide compositions
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
AU6124296A (en) Novel dolastatin derivatives, their preparation and use
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU6639096A (en) Corneal irrigation cannula
AU5229498A (en) Mutants of the lag-3 proteins, products for the expression of these mutants and use
AU4061597A (en) Treatment of the common cold or allergic rhinitis
AU4329396A (en) Use of 3,4-diphenylchromans
AU4131296A (en) Treatment of disorders with duloxetine
AU4018897A (en) Novel 3,4-diaryloxazolone derivatives, methods of preparation and therapeutic uses thereof
AU2467395A (en) Novel ophthalmologic uses of protein c
AU6264596A (en) Diagnosis, prognosis and monitoring of angiogenesis dependen t diseases
AU5395194A (en) Process for the manufacture of 1,1,1,2-tetrafluoro-2- chloroethane and of pentafluoroethane
AU4561497A (en) Human rantes mutants incapable of aggregate formation
IL125002A0 (en) Novel substituted 4-(1H-benzimidazol-2-yl) [1,4] diazepanes useful for the treatment of allergic diseases
AU1952497A (en) Novel antibody-cytokine fusion protein, and methods of making and using the same
AU6714996A (en) 2-(fluorenonyl)-carbapenems, compositions and methods of use
AU3467697A (en) 3'-oximino-2',3'-dideoxynucleosides and derivatives of the same
AU2776497A (en) Treatment of asthma with tnfr-ig
AU6062796A (en) The process of asphalt purification and the composition of modified asphalt
AU2415599A (en) Rantes mutants and therapeutic applications thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2224646

Country of ref document: CA

Ref country code: CA

Ref document number: 2224646

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 1997 502784

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996917584

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996917584

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1996917584

Country of ref document: EP